Phase 1 Study to Determine the Metabolism and Clearance of Baxdrostat

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Hypertension

Treatments: Drug: baxdrostat

Study type: Interventional

Funder types: Industry

Identifiers

NCT05961384

CIN-107-117

Details and patient eligibility

About

This was a Phase 1, open-label, single dose study in healthy male subjects. The goals of this clinical trial were to determine how baxdrostat might be absorbed and metabolized using radioactive [14C] labeled baxdrostat. Subjects were administered a single oral dose of 10 mg containing approximately 100 μCi of [14C] baxdrostat. Subjects were to be confined to the study site for 9 to 15 days for blood, urine, and feces collections.

Enrollment: 8 patients

Sex: Male

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Subjects must meet the following inclusion criteria:

• Be males of any race between 18 and 55 years of age
• Have a body mass index between 18.0 and 32.0 kg/m2
• Be in good health, determined by no clinically significant findings from medical history
• Have normal renal function, defined as estimated GFR ≥70 mL/min/1.73 m2
• Agree to use contraception
• Be able to comprehend and willing to sign an ICF and to abide by the study restrictions
• Have a history of a minimum of 1 bowel movement per day
• Agree to refrain from donation of sperm from check-in until 90 days after discharge

Main Exclusion Criteria:

• Significant history or clinical manifestation of any diseases as determined by the investigator
• Prolonged QTcF (>450 msec)
• Confirmed (eg, 2 consecutive measurements) systolic BP >140 or <90 mmHg, diastolic BP >90 or <50 mmHg, and pulse rate >100 or <45 beats per minute (bpm).
• Postural tachycardia (ie, >30 bpm upon standing) or orthostatic hypotension (ie, a fall in systolic BP of ≥20 mmHg or diastolic BP of ≥10 mmHg upon standing).
• Serum potassium >upper limit of normal (5.3 mmol/L; ULN) of the reference range and serum sodium <lower limit of normal (135 mmol/L) of the reference range
• Aspartate aminotransferase, alanine aminotransferase, or total bilirubin values >1.2 × ULN.
• A known history of porphyria, myopathy, or active liver disease
• Use of any prescription medications
• Corticosteroid use (systemic or extensive topical use) within 3 months prior to dosing
• Subjects who have participated in more than 3 radiolabeled drug studies in the last 12 months

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

8 participants in 1 patient group

10 mg [14C]-bexdrostat

Experimental group

Description:

single oral dose of 10 mg baxdrostat containing 100 μCi of \[14C\] baxdrostat

Treatment:

Drug: baxdrostat